There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and found to be adequate. Pharmaceuticals already on the market, such as Vitamin D do not have to and may never have had do so, and the financial incentives to do so are relatively insignificant. Thus lack of approval of such<unk> s implies neither efficacy nor lack of efficacy. In general, novel pharmaceuticals cannot enter a market without government approval; standards and political influences vary.
Multiple sclerosis drug pipeline
Multiple sclerosis research
Amyotrophic lateral sclerosis research
Multiple sclerosis biomarkers
Multiple sclerosis functional composite
Byzantine medicine
Rehabilitation in spinal cord injury
Experimental cancer treatment